{{Infobox drug
| IUPAC_name        = 5-[(3-chlorophenyl)amino]benzo[''c''][2,6]naphthyridine-8-carboxylic acid
| image             = Silmitasertib.svg
| alt               = 
| caption           =
<!-- Clinical data -->
| pronounce         =
| tradename         = 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_AU_comment = 
| pregnancy_US      = <!-- A/B/C/D/X/N -->
| pregnancy_category= 
| routes_of_administration = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_DE = <!-- Anlage I, II, III -->
| legal_NZ = <!-- Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_US = <!-- OTC/Rx-only/Schedule I, II, III, IV, V -->
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_status      = <!-- Free text -->
<!-- Pharmacokinetic data -->
| bioavailability   = Orally bioavailable
| protein_bound     = 
| metabolism        = 
| metabolites       =
| onset             = 
| elimination_half-life = 
| duration_of_action =
| excretion         = 
<!-- Identifiers -->
| CAS_number        = 1009820-21-6
| class             = 
| ATCvet            = 
| ATC_prefix        = None
| ATC_suffix        = 
| PubChem           = 24748573
| DrugBank          = 
| synonyms          = CX-4945
|  ChemSpiderID = 25057795
| StdInChI          = InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)
| StdInChIKey       = MUOKSQABCJCOPU-UHFFFAOYSA-N
| SMILES            = C1=CC(=CC(=C1)Cl)NC2=C3C=CN=CC3=C4C=CC(=CC4=N2)C(=O)O
| UNII              = C6RWP0N0L2
| ChEMBL            = 1230165
| PDB_ligand        = 3NG
<!-- Chemical and physical data -->
| C=19 | H=12 | Cl=1 | N=3 | O=2
| molecular_weight  = 
}}

'''Silmitasertib''' ([[International Nonproprietary Name|INN]]), codenamed '''CX-4945''', is a [[small molecule|small-molecule]] inhibitor of protein kinase CK2 ([[casein kinase 2|casein kinase II]]), a constitutively active [[serine/threonine-specific protein kinase]] that is [[gene expression|overexpressed]] in several types of [[tumor]]s.

Silmitasertib is in clinical trials for use as an [[Adjuvant therapy|adjunct]] to [[chemotherapy]] in the treatment of [[cholangiocarcinoma]] (bile duct cancer), and in [[preclinical development]] for other cancers, including [[tumors of the hematopoietic and lymphoid tissues|hematological and lymphoid malignancies]].<ref name="pmid27719640">{{cite journal |authors=Gowda C, Sachdev M, Muthusami S, Kapadia M, Petrovic-Dovat L, Hartman M, Ding Y, Song C, Payne JL, Tan BH, Dovat S |title=Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies |journal=[[Current Pharmaceutical Design]] |volume=23 |issue=1 |pages=95–107 |year=2017 |pmid=27719640 |doi=10.2174/1381612822666161006154311}}</ref>

In January 2017, it was granted [[orphan drug]] status by the U.S. [[Food and Drug Administration]] for advanced cholangiocarcinoma. It is being developed by Senhwa Biosciences of Taiwan.<ref>{{cite journal |authors=[No authors listed] |title=CX-4945 granted orphan drug designation |journal=Oncology Times |volume=39 |issue=5 |pages=23 |year=2017 |doi=10.1097/01.COT.0000514203.35081.69}}</ref>

==Mechanism of action==
Silmitasertib interacts [[competitive inhibition|competitively]] with the [[adenosine triphosphate|ATP]]-binding site of [[Casein kinase 2, alpha 1|CK2 subunit alpha]]. This leads to inhibition of several downstream [[cell signaling|signaling pathways]], including [[Akt/PKB signaling pathway|PI3K/Akt]].<ref name="pmid25873900">{{cite journal |authors=Chon HJ, Bae KJ, Lee Y, Kim J |title=The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies |journal=[[Frontiers in Pharmacology]] |volume=6 |issue= |pages=70 |year=2015 |pmid=25873900 |pmc=4379896 |doi=10.3389/fphar.2015.00070}}</ref><ref name="pmid21159648">{{cite journal |authors=Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C, Proffitt C, Schwaebe MK, Ryckman DM, Rice WG, Anderes K |title=CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy |journal=Cancer Research |volume=70 |issue=24 |pages=10288–98 |year=2010 |pmid=21159648 |doi=10.1158/0008-5472.CAN-10-1893}}</ref>

==History==
CX-4945 was originated by now-defunct Cylene Pharmaceuticals of San Diego, California, as the culmination of a lengthy process of [[drug design|rational, structure-based]] [[molecular modification]] of a [[lead compound]] known to have [[PARP inhibitor]] activity.<ref name="pmid21174434">{{cite journal |authors=Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, Vialettes A, Whitten JP, Chen TK, Darjania L, Stansfield R, Anderes K, Bliesath J, Drygin D, Ho C, Omori M, Proffitt C, Streiner N, Trent K, Rice WG, Ryckman DM |title=Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer |journal=[[Journal of Medicinal Chemistry]] |volume=54 |issue=2 |pages=635–54 |year=2011 |pmid=21174434 |doi=10.1021/jm101251q |url=}}</ref> Among a large series of compounds built around a benzo[''c'']-[2,6][[naphthyridine]]-8-carboxylic acid scaffold, CX-4945 was chosen for its high potency and selectivity as an inhibitor of CK2.<ref name="pmid21174434"/>

Preclinical [[pharmacokinetics]] studies conducted in mice, rats, and dogs confirmed that CX-4945 had satisfactory [[bioavailability]] when given by mouth and did not block [[cytochrome P450]], while experiments in mice confirmed its inhibition of solid-tumor growth in a [[dose–response relationship|dose-dependent]] manner.<ref name="pmid21159648"/><ref name="pmid21174434"/>

Clinical trials in humans began in 2010, making CK-4945 the first CK2 inhibitor to reach this stage of drug development.<ref name="pmid21159648"/><ref name="pmid21174434"/> The [[International Nonproprietary Name]] '''silmitasertib''' was proposed in 2010 and recommended by the [[World Health Organization]] in 2011.<ref name="pINN">{{cite journal | title=International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 103 | journal=WHO Drug Information | volume=24 | issue=2 | year=2010 | authors=World Health Organization | pages=166–7 | url=http://apps.who.int/iris/bitstream/10665/74553/1/24_2_2010_INN103.pdf}}</ref><ref name="rINN">{{cite journal | title=International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 66 | journal=WHO Drug Information | volume=25 | issue=3 | year=2011 | authors=World Health Organization | pages=329 | url=http://www.who.int/medicines/publications/druginformation/innlists/RL66_final.pdf}}</ref>

==References==
{{reflist}}

{{Extracellular chemotherapeutic agents}}

[[Category:Naphthyridines]]
[[Category:Orphan drugs]]
[[Category:Protein kinase inhibitors]]
[[Category:Carboxylic acids]]
[[Category:Chloroarenes]]

{{antineoplastic-drug-stub}}